Sequential sorafenib and regorafenib in patients with advanced HCC
Sequential sorafenib and regorafenib in patients with advanced HCC
Dr. Mohamed Bouattour
Dr. Mohamed Bouattour discusses the recently published additional analyses from the phase 3 RESORCE trial on sequential treatment with sorafenib followed by regorafenib for hepatocellular carcinoma.
Expert View |
5 min
I agree that this educational programme:
Was valuable to me:
1/3
Other programmes of interest
Other programmes developed by Dr. Mohamed Bouattour

Dr. Mohamed Bouattour
Hepatologist and Gastroenterologist
Beaujon University Hospital
France